Pancreatic Cancer Research

ResearcherCornell UniversityActive in the last 2 years

Allyson J. Ocean

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3799-9527; OpenAlex author ID A5049924653. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
70
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: 2 papers · 2016: none · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 3 papers · 2023: none · 2024: 1 paper

Papers 10

  1. A Randomized Trial of Two Remote Health Care Delivery Models on the Uptake of Genetic Testing and Impact on Patient-Reported Psychological Outcomes in Families… Co-author DOI 10.1053/j.gastro.2024.01.042↗
  2. A randomized phase II study of SM-88 plus methoxsalen, phenytoin, and sirolimus in patients with metastatic pancreatic cancer treated in the second line and be… Co-author DOI 10.1002/cam4.4768↗
  3. A multicenter phase 1/2 study investigating the safety, pharmacokinetics, pharmacodynamics and efficacy of a small molecule antimetabolite, RX-3117, plus nab-p… Last author DOI 10.1007/s10637-021-01164-9↗
  4. Twitter Conversations About Pancreatic Cancer by Health Care Providers and the General Public: Thematic Analysis. Last author DOI 10.2196/31388↗
  5. Novel Models of Genetic Education and Testing for Pancreatic Cancer Interception: Preliminary Results from the GENERATE Study. Co-author DOI 10.1158/1940-6207.capr-20-0642↗
  6. A Phase I/II Open-Label Multicenter Single-Arm Study of FABLOx (Metronomic 5-Fluorouracil Plus nab-Paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin) in Pat… Co-author DOI 10.1089/pancan.2019.0012↗
  7. Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-18-0349↗
  8. (90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior ther… Co-author DOI 10.1016/j.ejca.2015.06.119↗
  9. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Co-author DOI 10.1038/ncb3169↗
  10. Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial. Co-author DOI 10.1002/cncr.27592↗

Closest collaborators

The 25 strongest of 70 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Anirban Maitra · 3 shared papers, 2021–2024 · strength 0.40
  2. Vincent J. Picozzi · 3 shared papers, 2015–2022 · strength 0.26
  3. Barbara J. Kenner · 2 shared papers, 2021–2024 · strength 0.24
  4. Meghan L. Underhill-Blazey · 2 shared papers, 2021–2024 · strength 0.24
  5. C. Sloane Furniss · 2 shared papers, 2021–2024 · strength 0.24
  6. Tara B. Coffin · 2 shared papers, 2021–2024 · strength 0.24
  7. Alison P. Klein · 2 shared papers, 2021–2024 · strength 0.24
  8. Matthew B.B. Yurgelun · 2 shared papers, 2021–2024 · strength 0.24
  9. Michael Goggins · 2 shared papers, 2021–2024 · strength 0.24
  10. Nicolette Juliana Rodriguez · 2 shared papers, 2021–2024 · strength 0.24
  11. Sapna Syngal · 2 shared papers, 2021–2024 · strength 0.24
  12. Andrew M. Lowy · 2 shared papers, 2021–2024 · strength 0.24
  13. Gloria M. Petersen · 2 shared papers, 2021–2024 · strength 0.24
  14. Florencia M. McAllister · 2 shared papers, 2021–2024 · strength 0.24
  15. Philip A. Philip · 2 shared papers, 2019–2022 · strength 0.23
  16. Muhammad Shaalan Beg · 1 shared paper, 2022 · strength 0.16
  17. Niraj Jaysukh Gusani · 1 shared paper, 2022 · strength 0.16
  18. Udhayvir Singh Grewal · 1 shared paper, 2022 · strength 0.16
  19. Arjun Gupta · 1 shared paper, 2022 · strength 0.16
  20. Emil Lou · 1 shared paper, 2022 · strength 0.16
  21. Mitesh J. Borad · 1 shared paper, 2022 · strength 0.14
  22. Marion L. Hartley · 1 shared paper, 2022 · strength 0.14
  23. Andrea J. Bullock · 1 shared paper, 2022 · strength 0.14
  24. Dae Won Kim · 1 shared paper, 2022 · strength 0.14
  25. Daruka Mahadevan · 1 shared paper, 2022 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.